Nucorion in-licensed Ligand Pharmaceuticals' LTP Technology, a novel prodrug technology platform designed to selectively deliver a range of active pharmaceutical agents to the liver. It works by chemically modifying a biologically active molecule into an inactive prodrug form that will be administered and later activated in the liver by certain enzymes mainly expressed in the liver. The technology can be used to improve activity and/or safety of an existing drug or to develop new agents to treat liver diseases or diseases caused by homeostasis imbalance of circulating biomolecules controlled by the liver such as lipids and glucose, and is especially applicable to metabolic and cardiovascular diseases. Ligand's LTP Technology has expanded chemical class applicability and also removes certain by-products as compared to other targeting technologies.
Nucorion in-licensed certain novel nucleos(t)ide analog compound series developed in professor Zucai Suo’s laboratories at the Ohio State University. The compounds were designed to circumvent nucleoside-based anti-cancer drug resistances by addressing multiple known resistance incurring mechanisms. The technology can be used to improve certain existing nucleoside-based anti-cancer drugs for better efficacy and longer duration for the treatment of various solid tumors.
